Analytical Data
-
基因名
PRAMEF5
- Application
-
别名
PRAMEF5; PRAMEF23; PRAMEF5L; PRAME family member 5
-
种属
Human
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q5TYX0
-
表达区间
1-476 aa
-
氨基酸序列
MSIRTPPRLL ELAGRSLLRD QALAMSTLEE LPTELFPPLF MEAFSRRRCE ALKLMVQAWP FRRLPLRPLI KMPCLEAFQA VLDGLDALLT QGVHPRRWKL QVLDLQDVCE NFWMVWSEAM AHGCFLNAKR NKKPVQDCPR MRGQQPLTVF VELWLKNRTL DEYLTCLLLW VKQRKDLLHL CCKKLKILGM PFRNIRSILK MVNLDCIQEV EVNCKWVLPI LTQFTPYLGH MRNLQKLVLS HMDVSRYVSP EQKKEIVTQF TTQFLKLCCL QKLSMNSVSF LEGHLDQLLS CLKTSLKVLT ITNCVLLESD LKHLSQCPSI SQLKTLDLSG IRLTNYSLVP LQILLEKVAA TLEYLDLDDC GIIDSQVNAI LPALSRCFEL NTFSFCGNPI SMATLENLLS HTIILKNLCV ELYPAPRESY DADGTLCWSR FAQIRAELMK RVRDLRHPKR ILFCTDCCPD CGNRSFYDLE ADQCCC
-
分子量
54.8 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
PRAMEF5, a member of the cancer/testis antigen family, has garnered significant attention in cancer research due to its differential expression patterns in various tumors and limited presence in normal tissues, specifically in the testis. This unique expression profile makes PRAMEF5 an attractive target for immunotherapy and cancer diagnostics. Research suggests that PRAMEF5 may play a role in tumorigenesis and could potentially be involved in the modulation of the immune response against cancer cells. Previous studies have demonstrated that PRAMEF5 can induce T-cell responses, indicating its potential as a candidate for peptide-based vaccines. The reconstitution of PRAMEF5 as a recombinant protein allows for in-depth studies of its immunogenicity and function in a controlled laboratory setting. Moreover, understanding the molecular mechanisms underlying PRAMEF5 expression could provide insights into its role in cancer biology and aid in the development of novel therapeutic strategies aimed at harnessing the immune system to target tumors. This research not only paves the way for potential clinical applications but also enhances the overall understanding of the immune landscape in cancer, positioning PRAMEF5 as a significant player in the field of tumor immunology.
